Value based prices

Levaggi R., Pertile P. (2020). Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition. Applied Health Economics and Health Policy, pp. 1-13.

PubblicazioniPaolo Pertile 02/12/2020

Levati R., Pertile P. (2020). Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition. Applied Health Economics and Health Policy, Volume 18,…

Levaggi R., Pertile P. (2020). Which valued-based price when patients are heterogeneous? Health economics, Volume 29, Issue 8, pp. 923-935.

PubblicazioniPaolo Pertile 26/10/2020

Levaggi R., Pertile P. (2020) Which valued-based price when patients are heterogeneous? Health economics, Volume 29, Issue 8, pp. 923-935. Abstract: We use a…

Levaggi R., Pertile P. (2020). Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”. Applied health economics and health policy, 18(3), pp. 455-456.

PubblicazioniPaolo Pertile 26/10/2020

Levaggi R., Pertile P. (2020). Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”. Applied health…

Tag: Value based prices

Levaggi R., Pertile P. (2020). Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition. Applied Health Economics and Health Policy, pp. 1-13.

Levaggi R., Pertile P. (2020). Which valued-based price when patients are heterogeneous? Health economics, Volume 29, Issue 8, pp. 923-935.

Levaggi R., Pertile P. (2020). Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”. Applied health economics and health policy, 18(3), pp. 455-456.